Onkologie, Hämatologie - Daten und Informationen
SitemapSitemap  


Literaturreferenzen des Artikels "Hämoglobinopathien und Thalassämien"

Autor/en: M.R. Clemens, R. Mahlberg
Letzte Änderung: 09.12.2003
  • Atweh GF, Loukopoulos D.
    Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia.
    Semin Hematol. 2001;38(4):367-73. Review. PM:11605172
    [Medline]


  • Bernaudin F.
    [Results and current indications of bone marrow allograft in sickle cell disease].
    Pathol Biol (Paris). 1999;47(1):59-64. French. PM:10081781
    [Medline]


  • Bernini JC, Rogers ZR, Sandler ES, Reisch JS, Quinn CT, Buchanan GR.
    Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease.
    Blood. 1998;92(9):3082-9. PM:9787142
    [Medline]


  • Bernini LF, Harteveld CL.
    Alpha-thalassaemia.
    Baillieres Clin Haematol. 1998;11(1):53-90. Review. PM:10872473
    [Medline]


  • Carache.
    Mechanisms of action of hydroxyurea in the management of sickle cell anemia in adults.
    Semin Hematol 1997;34(Suppl3):15-21.


  • Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F.
    Safety profile of the oral iron chelator deferiprone: a multicentre study.
    Br J Haematol. 2000 Feb;108(2):305-12. PM:10691860
    [Medline]


  • Dickerhoff R et al.
    Sichelzellerkrankungen in Deutschland.
    Dt Ärzteblatt 1998;95:A1675-1679.


  • Dondorp AM, Chotivanich KT, Fucharoen S, Silamut K, Vreeken J, Kager PA, White NJ.
    Red cell deformability, splenic function and anaemia in thalassaemia.
    Br J Haematol. 1999 ;105(2):505-8. PM:10233428
    [Medline]


  • Flint J, Harding RM, Boyce AJ, Clegg JB.
    The population genetics of the haemoglobinopathies.
    Baillieres Clin Haematol. 1998;11(1):1-51. Review. PM:10872472
    [Medline]


  • La Nasa G, Giardini C, Argiolu F, Locatelli F, Arras M, De Stefano P, Ledda A, Pizzati A, Sanna MA, Vacca A, Lucarelli G, Contu L.
    Unrelated donor bone marrow transplantation for thalassemia:the effect of extended haplotypes.
    Blood. 2002;99(12):4350-6. PM:12036861
    [Medline]


  • Martin et al.
    Correction of beta-thalassemia major with umbilical cord blood tranplantation from a related haploidentical donor.
    Blood, Proceedings ASH Abstract 1997;4536.


  • Morris CR, Kuypers FA, Larkin S, Sweeters N, Simon J, Vichinsky EP, Styles
    LA.
    Arginine therapy:a novel strategy to induce nitric oxide production in sickle cell disease.
    Br J Haematol. 2000;111(2):498-500. PM:11122090
    [Medline]


  • Morris K.
    Addressing the crisis of care for sickle-cell disease.
    Lancet. 1999;353(9163):1504. PM:10232329
    [Medline]


  • Olivieri NF.
    The beta-thalassemias.
    N Engl J Med. 1999;341(2):99-109. PM:10395635
    [Medline]


  • Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA.
    Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    N Engl J Med. 1998;339(7):417-23. PM:9700174
    [Medline]


  • Olivieri NF, Brittenham GM.
    Iron-chelating therapy and the treatment of thalassemia.
    Blood. 1997;89(3):739-61. PM:9028304
    [Medline]


  • Roberts I.
    Current status of allogeneic transplantation for haemoglobinopathies.
    Br J Haematol. 1997;98(1):1-7. PM:9233555
    [Medline]


  • Rogers ZR.
    Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
    Semin Hematol. 1997;34(3 Suppl 3):42-7. PM:9317200
    [Medline]


  • Rogers GP.
    Overview of pathophysiology and rationale for the treatment of sickle cell anemia.
    Semin Hematol 1997;34(Suppl3):2-7.


  • Storb RF, Lucarelli G, McSweeney PA, Childs RW.
    Hematopoietic cell transplantation for benign hematological disorders and solid tumors.
    Hematology (Am Soc Hematol Educ Program) 2003;372-97. PM:14633791
    [Medline]


  • Styles LA, Vichinsky E.
    Effects of a long-term transfusion regimen on sickle cell-related illnesses.
    J Pediatr. 1994;125(6 Pt 1):909-11. PM:7996363
    [Medline]


  • Tondury P, Zimmermann A, Nielsen P, Hirt A.
    Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients.
    Br J Haematol. 1998;101(3):413-5. PM:9633879
    [Medline]


  • Vichinsky E.
    New therapies in sickle cell disease.
    Lancet. 2002;360(9333):629-31. Review. PM:12241949
    [Medline]


  • Vichinsky EP.
    Hydroxyurea in children:present and future.
    Semin Hematol. 1997;34(3 Suppl 3):22-9. Review. PM:9317198
    [Medline]


  • Walters MC, Patience M, Leisenring W, Rogers ZR, Aquino VM, Buchanan GR, Roberts IA, Yeager AM, Hsu L, Adamkiewicz T, Kurtzberg J, Vichinsky E, Storer B, Storb R, Sullivan KM.
    Multicenter Investigation of Bone Marrow Transplantation for Sickle Cell Disease. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia.
    Biol Blood Marrow Transplant. 2001;7(12):665-73. PM:11787529
    [Medline]


  • Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, Gamberini MR, Schwartz E, Cohen AR. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood. 2002 1;100(5):1566-9. PM:12176871 (Erratum in: Blood. 2003 Apr 1;101(7):2460.)
    [Medline]


  • Wonke B, Wright C, Hoffbrand AV.
    Combined therapy with deferiprone and desferrioxamine.
    Br J Haematol. 1998;103(2):361-4. PM:9827905
    [Medline]


Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch:
mehr 
[Mehr]